LENZ Therapeutics Sees Q4 Revenue of $1.89M, EPS -$0.96; 2026 Estimates Cut
LENZ Therapeutics signals Q4 2025 revenue of $1.89 million with EPS of -$0.96 and forecasts full-year 2025 revenue at $19.12 million and -$2.63 per share loss. Analysts trimmed 2026 revenue estimates to $49.18 million and deepened EPS loss outlook to -$2.93 per share.
1. Q4 2025 Earnings Estimates
LENZ Therapeutics is expected to report Q4 2025 revenue of $1.89 million and a loss of $0.96 per share, with full-year 2025 revenue forecast at $19.12 million and a per-share loss of $2.63.
2. 2026 Estimate Revisions
Analysts have lowered full-year 2026 revenue forecasts from $52.26 million to $49.18 million and deepened the EPS loss outlook from $2.62 to $2.93 per share over the past 90 days.
3. Q3 2025 Performance Recap
In Q3 2025, LENZ Therapeutics generated $12.50 million in revenue, beating estimates by 83%, and posted a $0.59 per share loss, outperforming forecasts by 11.5%, yet shares fell 23.5% the following trading day.
4. Analyst Targets and Ratings
Analysts’ one-year price targets average $48.20, ranging from $35.00 to $62.00, implying roughly 360% upside, while a proprietary valuation model suggests a zero fair value and the consensus rating stands at 1.4 on a 1–5 Buy–Sell scale.